Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Towa Files Additional Request for Livalo Patent Invalidity in December 2020
April 16, 2021
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Rohto Licenses COVID-19 Drug Candidate from Japan Biotech
April 15, 2021
- Ono Files Opdivo for Cancer of Unknown Primary in Japan
April 15, 2021
- Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief
April 14, 2021
- Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
April 14, 2021
- Otsuka, Lundbeck to Carry On Multinational PIII of Brexpiprazole for Agitation in Alzheimer’s
April 14, 2021
- Urovant’s OAB Med Gemtesa Now Available in US
April 14, 2021
- Kobayashi Kako Recalling 4 Mesalazine Products due to OOS
April 14, 2021
- Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
- Nipro Gets Approval of Seven-Dose Syringe for Pfizer COVID-19 Vaccine
April 13, 2021
- MSD Files Keytruda for RCC in Combo Therapy with Lenvima
April 13, 2021
- Maruho Aspires to Get Back on Growth Track on New Drug Launches: President
April 12, 2021
- Kobayashi Kako’s Seima Factory Operations Still Halted Even after 60-Day Order Lifted
April 12, 2021
- Daiichi Sankyo Kicks Off Japan PII for Pexidartinib for TGCT
April 12, 2021
- Drug Reps Increase Online Meetings in February amid Emergency: Intage
April 9, 2021
- Hisamitsu’s Sales Sag 18.8% on Price Cuts, Gx, COVID-19
April 9, 2021
- Nichi-Iko Recalls 2 Products over Quality Issues Days after Biz Suspension Lifted
April 9, 2021
- Daiichi Sankyo Kicks Off PI/II Study for Menin Inhibitor in AML/ALL
April 9, 2021
- Teijin Pharma Set to Transform Biz, Weather Feburic Patent Cliff with Takeda’s DPP-4s
April 8, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…